12 Recent Discoveries in Alzheimer's Research That Could Change Treatment

6. Cellular Senescence and Aging Mechanisms

The identification of cellular senescence as a key driver of Alzheimer's disease has provided new insights into the fundamental aging processes that contribute to neurodegeneration. Senescent cells are aged cells that have stopped dividing but remain metabolically active, secreting a complex mixture of inflammatory factors, proteases, and growth factors known as the senescence-associated secretory phenotype (SASP). These senescent cells accumulate in the brain with age and have been found in significantly higher numbers in individuals with Alzheimer's disease, particularly in regions most affected by the disease such as the hippocampus and cortex. The SASP factors released by senescent cells create a chronic inflammatory environment that damages healthy neurons, promotes tau pathology, and impairs the function of other brain cells including microglia and astrocytes. Recent studies have shown that senescent cells can also disrupt normal brain metabolism, reduce neuroplasticity, and interfere with the brain's ability to form new neural connections. Perhaps most importantly, researchers have discovered that selectively eliminating senescent cells using drugs called senolytics can significantly improve cognitive function and reduce pathological changes in animal models of Alzheimer's disease. This has led to clinical trials investigating whether senolytic therapies, such as dasatinib and quercetin combinations, can slow cognitive decline in humans. The senescence pathway also offers new biomarkers for early disease detection and monitoring treatment response, as senescence markers in blood and cerebrospinal fluid correlate with disease severity and progression.